Lower Diabetes Risk Linked to Osteoporosis Drug Denosumab Lower Diabetes Risk Linked to Osteoporosis Drug Denosumab
The lower risk for diabetes associated with continued denosumab use in older adults added new evidence to consider when choosing an osteoporosis treatment option.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 1, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news

Sandoz receives Health Canada approval for Jubbonti ®, first and only denosumab biosimilar for treatment of osteoporosis
Biosimilar Jubbonti® approved for all indications of Prolia* reference medicine. • Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass. • Results confirm that Jubbonti® provides same risks and benefits in terms of…#prolia #sandoz #boucherville #quebec #sandozcanada #healthcanada #jubbonti #canada1 #jeanpierreraynauld #frcpc (Source: Reuters: Health)
Source: Reuters: Health - February 20, 2024 Category: Consumer Health News Source Type: news

Denosumab Protective Against Diabetes?
(MedPage Today) -- Continued treatment with the osteoporosis drug denosumab (Prolia) was tied to a lower risk of developing diabetes in a Taiwanese cohort study. In a propensity score-matched analysis, adherence to denosumab for osteoporosis was... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 13, 2024 Category: Cardiology Source Type: news

Denosumab Linked to Severe Hypocalcemia in Dialysis-Dependent Seniors
THURSDAY, Jan. 25, 2024 -- For female dialysis-dependent patients aged 65 years or older treated for osteoporosis, denosumab is associated with an increased incidence of severe or very severe hypocalcemia, according to a study published online Jan.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 25, 2024 Category: Pharmaceuticals Source Type: news

Severe Hypocalcemia Risk in Dialysis Patients With Denosumab Severe Hypocalcemia Risk in Dialysis Patients With Denosumab
New research backed up previous findings, showing a substantially higher risk for severe hypocalcemia in older patients on kidney dialysis than in those treated with oral bisphosphonates.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 22, 2024 Category: Consumer Health News Tags: Nephrology Source Type: news

FDA Adds Warning to Osteoporosis Drug for Hypocalcemia Risk FDA Adds Warning to Osteoporosis Drug for Hypocalcemia Risk
Based on a completed data review, the agency concluded that denosumab increases the risk for severe hypocalcemia in patients with chronic kidney disease.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - January 19, 2024 Category: Internal Medicine Tags: Nephrology Source Type: news

Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning
The FDA has added a serious warning to the prescribing information for Amgen Inc’s AMGN drug Prolia (denosumab), emphasizing an increased risk of severely low calcium levels in specific patient groups. Amgen’s Prolia, initially approved in 2010 for treating bone loss in postmenopausal women and…#fda #amgenincs #prolia #amgen #merckcoincs #mrkfosamax #xgeva #evenity #lungcancer (Source: Reuters: Health)
Source: Reuters: Health - January 19, 2024 Category: Consumer Health News Source Type: news

FDA Slaps Boxed Warning on Osteoporosis Drug
(MedPage Today) -- The FDA added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) over the risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD), the agency announced Friday. After a review... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 19, 2024 Category: Endocrinology Source Type: news

Prolia (denosumab): Drug Safety Communication -  FDA Adds Boxed Warning for Increased Risk of Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease
FDA Adds Boxed Warning for Increased Risk of Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease Taking Osteoporosis Medicine Prolia (Denosumab): FDA Safety Communication. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Calcium Levels Quickly Become Critical for Many Denosumab-Treated Women on Dialysis
(MedPage Today) -- Many women on dialysis quickly developed severe hypocalcemia after starting denosumab (Prolia) for osteoporosis, Medicare data showed. During the first 12 weeks of treatment, 41.1% of women on denosumab developed severe hypocalcemia... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 19, 2024 Category: Endocrinology Source Type: news

High body fat raises fracture risk in women treated for breast cancer
Women with high body fat undergoing early breast cancer treatment may be at higher risk for vertebral fractures, despite the use of bone health drugs, according to a study published January 10 in JAMA Network Open. In a study of patients who received aromatase inhibitors and denosumab over four years, dual-energy x-ray absorptiometry (DEXA) scans showed that high baseline fat body mass was independently associated with vertebral fractures after 18 months, wrote lead author Deborah Cosentini, MD, of the University of Brescia in Italy, and colleagues. “These findings suggest that fat body mass may promote skeletal fragil...
Source: AuntMinnie.com Headlines - January 12, 2024 Category: Radiology Authors: Will Morton Tags: Digital X-Ray Womens Imaging Source Type: news

5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and likely 2024. Demand is growing as the country ages; pricing remains solid and plain and…#treasury #amgen #amgeninc #neulasta #prolia #xgeva #otezla #behcet #aranesp #kyprolis (Source: Reuters: Health)
Source: Reuters: Health - November 11, 2023 Category: Consumer Health News Source Type: news

Premenopausal Osteoporosis: What to Do After Denosumab Premenopausal Osteoporosis: What to Do After Denosumab
Extension trial gives insight into treatment order for a little-studied population of premenopausal women.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 19, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Fracture Reduction Greater with Denosumab vs Zoledronic Acid Fracture Reduction Greater with Denosumab vs Zoledronic Acid
In the absence of a randomized comparison trial on fracture risk reduction, researchers use negative control outcome to compare the two drugs.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 16, 2023 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

Romosozumab Tops Denosumab in Treating GIOP Romosozumab Tops Denosumab in Treating GIOP
In a small study, patients treated with romosozumab had a greater increase in spine bone mineral density, compared with the denosumab group after 1 year.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2023 Category: Consumer Health News Tags: Rheumatology News Source Type: news